Monoclonal Antibody Pipeline and Market Reports Released for 2026

Three comprehensive market intelligence reports have been released examining the monoclonal antibody therapeutic landscape, covering pipeline developments, competitive dynamics, and market forecasts through 2033.

A report on CD47 and SIRP-alpha targeted immunotherapy provides an up-to-date competitor evaluation in the field of emerging therapy candidates in research and development targeting CD47 or SIRP-a. The report lists active CD47 and SIRP-a targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of CD47 and SIRP-a inhibitors by drug modality, including antibodies, fusion proteins, protein biologics, RNA/mRNA or small molecules.

The phagocytic activity of macrophages is regulated by both activating ("eat me") and inhibitory ("don't eat me") signals. CD47 serves as a critical "don't eat me" signal inhibiting phagocytosis by binding to signal regulatory protein alpha (SIRP-a) on the surface of macrophages. The CD47-SIRP-a interaction represents an important mechanism by which malignant cells evade macrophage-mediated destruction. CD47 is overexpressed in numerous hematological cancers and solid tumors, and high CD47 expression correlates with more aggressive disease and poorer clinical outcomes.

Preclinical studies have shown that interrupting the CD47-SIRP-a signaling pathway promotes anti-tumor activity against human cancers, both in vitro and in vivo. Dual function molecules are designed to bind CD47 and neutralize its suppressive signal, and deliver a pro-phagocytic ("eat me") signal through the Fc region, which binds to activating Fc receptors on the surface of macrophages. There are differences to be expected whether the Fc is of the IgG1 or IgG4 isotype or even inert (inactivated Fc).

Development of CD47 antibody as a cancer therapy is hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. A differentiation factor among competitor molecules is the virtue of not binding or reduced binding to CD47 on human red blood cells. This lowers the risk of serious anemia in patients, avoids the removal of the drug from the circulation by red blood cells ("antigen sink effect") and minimizes interference with laboratory blood typing tests. More than 20 distinct molecules targeting the CD47-SIRP-a pathway are in clinical development.

A separate competitive landscape report offers detailed analysis of the monoclonal antibody space encompassing 180+ companies and over 230 drugs. It assesses therapeutics based on product type, stage of development, route of administration, and molecule type. The report also identifies inactive pipeline products globally.

Monoclonal Antibodies (mAbs) represent a significant advancement in immunotherapy. They offer targeted treatment, especially in oncology, by honing in on specific antigens linked to tumor growth. Key types of mAbs include human, murine, humanized, and chimeric, each with distinct derivations from human and mouse proteins. Structurally, mAbs consist of a Y-shaped composition, allowing for high stability and flexibility. Most clinical mAbs are IgG-based, reflecting their robust efficacy.

The report documents several strategic collaborations from 2022-2023. In March 2023, Shanghai-Jacos Pharmaceuticals allied with Merck to assess JAB-BX102 with KEYTRUDA for advanced tumors. In the same month, Simcere partnered with MSD to research SIM0235 combined with KEYTRUDA in cancer patients, and BioNTech and OncoC4 initiated a collaboration on ONC-392, targeting CTLA-4 in cancers. In February 2023, Vir Biotechnology adjusted its partnership with GSK to persist in COVID-19 and viral therapy innovations.

In January 2023, CARsgen and Roche launched a collaborative study merging AB011 with atezolizumab for gastric carcinoma treatment. In November 2022, Exelixis and Sairopa advanced ADU-1805, aiming to enhance phagocytosis in cancer therapy. In October 2022, Compass Therapeutics collaborated with Merck to evaluate CTX-471 combined with KEYTRUDA. In September 2022, Abpro and Celltrion entered a $1.75 billion deal for developing the cancer molecule ABP 102.

OPDIVO, a PD-1 inhibitor, is approved worldwide for diverse cancers, leveraging the immune system to combat tumors. NUCALA targets eosinophilic inflammation and is approved for various conditions worldwide. Pipeline innovations include Ianalumab, a monoclonal antibody targeting B cell activation, currently in advanced phases for autoimmune and inflammatory diseases. Ziltivekimab is aimed at cardiovascular risk reduction in kidney disease patients. DISC-0974 targets key biological pathways and is already showing promising early results in addressing anemia.

A third report titled "Recombinant Monoclonal Antibody Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033" examines industry performance indicators, growth drivers, restraints, cost structures, and investment feasibility metrics including projected returns and margin outlook. The study delivers in-depth analysis of emerging trends, technological advancements, regulatory developments, and strategic opportunities shaping the market landscape.

Major market players covered include Roche Holding AG, Amgen Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., Novartis AG, Sanofi S.A., and Eli Lilly and Company. The recombinant monoclonal antibody market is segmented by type into human monoclonal antibodies, humanized monoclonal antibodies, and chimeric monoclonal antibodies. By application, the market covers oncology, autoimmune diseases, and infectious diseases.

The report presents a comprehensive regional assessment evaluating revenue performance, market share, consumption trends, growth rates, and strategic developments across North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The study follows a rigorous research framework combining extensive primary and secondary analysis to ensure accuracy and reliability, with market data collected, validated, and systematically evaluated by industry analysts to generate precise forecasts for the evaluation period 2026-2033.